ACE2 and Epstein-Barr virus infection: A study by Verma et al. (2021) indicated that the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) was upregulated during lytic EBV infection due to the EBV lytic activator, BZLF1 (Zta), targeting methylated promoters, thus increasing SARS-CoV-2 susceptibility in the human oral epithelium [197].